Recently, InnoBM Pharmaceuticals Co., Ltd. and Qilu Pharmaceutical Co., Ltd. have entered into a collaboration agreement for BM601—a metal embolic microsphere product developed by InnoBM for the TACE treatment of liver cancer. Under the agreement, InnoBM is eligible to receive milestone payments totaling over RMB 200 million, in addition to sales royalties and a share of overseas profits.

BM601 is a Class III medical device product developed by InnoBM based on original technology from Professor Liu’s team at Soochow University. Its unique mechanism of action is expected to significantly enhance the efficacy of transcatheter arterial chemoembolization (TACE). In early clinical studies involving patients with unresectable primary liver cancer, BM601 has shown considerable clinical benefits, demonstrating potential as a more effective therapeutic option for intermediate to advanced liver cancer patients.

The strategic collaboration between InnoBM and Qilu Pharmaceutical will combine R&D expertise with commercial strengths, creating a new model for translating scientific research: “original academic research → biotech transformation and clinical validation → industrialization and commercialization by big pharma.”

As InnoBM’s second out-licensing partnership, this collaboration with Qilu also underscores the industry’s recognition of InnoBM’s innovative and differentiated approach. We look forward to working closely with Qilu to advance the clinical development of this product and ultimately deliver this innovative treatment to liver cancer patients.